Furthermore, in patients with T2DM, liraglutide and semaglutide have been shown to reduce fat mass more than lean mass, thus improving the fat-to-lean ratio and overall body composition [5]
H., Brown-Frandsen, K., et al
Unlike many generic weight loss solutions that rely on extreme calorie cuts or synthetic appetite suppressants, AOD9604 operates at the molecular level to optimize the bodys inherent ability to burn fat
Cardiometabolic Improvements Weight loss was accompanied by clinically meaningful improvements across several cardiovascular risk markers, including reductions in: Waist circumference (mean reduction of approximately 24.1 cm at the highest dose) Non-HDL cholesterol Triglycerides Systolic blood pressure High-sensitivity C-reactive protein (hsCRP) a marker of inflammation These findings are particularly relevant for patients with obesity who also live with cardiometabolic conditions, where systemic risk reduction is as important as the weight loss itself
Because most T3 is primarily produced from peripheral 5-deiodinasemediated conversion of T4, decreased conversion and increased production of reverse T3 further lowers free T4 and T3 levels [32, 34,35,36] Elevated inflammatory cytokines including IL-1, IL-6, TNF- also suppress the release of thyroid-releasing hormone (TRH) and thyroid-stimulating hormone (TSH), and inhibit type 1 deiodinase activity, compounding the reduction in active T3 [35, 37]
